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SHORT REPORT
Estrogen use and early onset Alzheimer’s disease:
a population-based study
Arjen J C Slooter, Juliana Bronzova, Jaqueline C M Witteman, Christine Van Broeckhoven,
Albert Hofman, Cornelia M van Duijn
Abstract
Estrogen use may be protective for
Alzheimer’s disease with late onset. How-
ever, the eVects on early onset Alzheimer’s
disease are unclear. This issue was studied
in a population based setting. For each
female patient, a female control was
matched on age (within 5 years) and place
of residence. Information on estrogen use
and other risk factors were, for cases
(n=109) and controls (n=119), collected
from the next of kin by structured inter-
view. The strength of the association
between estrogen use and early onset
Alzheimer’s disease was studied using
conditional logistic regression with ad-
justment for age and education level.
There was an inverse association between
estrogen use and early onset Alzheimer’s
disease (adjusted odds ratio 0.34; 95%
confidence interval 0.12–0.94). The study
therefore suggests that estrogen use is
beneficial to Alzheimer’s disease with
early onset.
(J Neurol Neurosurg Psychiatry 1999;67:779–781)
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In recent years, there has been substantial
interest in the eVect of estrogen use on
Alzheimer’s disease. However, all studies until
now have reported on patients with late onset
Alzheimer’s disease.1 Early onset Alzheimer’s
disease is thought to be more often genetically
determined.2 An eVect of estrogen in this group
of patients will strengthen the evidence for a
beneficial role of estrogen in Alzheimer’s
disease. The aim of this population based study
was to investigate whether estrogen use is
related to early onset Alzheimer’s disease.
Subjects and methods
STUDY POPULATION
Patients were derived from a population based
study of early onset Alzheimer’s disease.
Details concerning ascertainment of the pa-
tients have been published elsewhere.3 All
patients diagnosed between 1980 and 1987,
from two regions in the Netherlands, were
included. The diagnosis of early onset
Alzheimer’s disease was made according to a
standard protocol similar to NINCDS-
ADRDA criteria.4 Inclusion criteria for enter-
ing this study were female sex, age of onset
before 65 years, and a slowly progressive
decline of intellectual functions. In addition,
the score on the clinical dementia rating scale5
should be greater than 0.5, the score on the
short portable mental status questionnaire6 less
than 20 (out of 30), and the score on the
Hachinski scale7 should be 7 or lower (out of
18). Exclusion criteria were abnormalities
other than cerebral atrophy on CT, and
evidence of focal dysfunction on EEG. Fur-
thermore, the dementia syndrome should not
be the result of vascular or metabolic disorders,
alcoholism, or depression. For each patient, a
control subject was selected matched for age
(within 5 years), sex, and place of residence.
These controls were selected at random (within
each age and sex category) from the municipal
population register. Overall, in 52% of cases,
the first consenting person served as a control,
in 34% it was the second selected person, in
12% the third, and in 2% the fourth. Cognitive
function in the controls was tested by short
portable mental status questionnaire and none
showed symptoms of dementia.8 Informed
consent was obtained from all participants.
After excluding women with missing data on
estrogen use (n=15 cases; n=5 controls) the
study population comprised 109 patients with
early onset Alzheimer’s disease and 119
controls.
DATA COLLECTION
Information on estrogen use, age at meno-
pause, vascular pathology, and education level
was obtained by structured questionnaire. For
both cases and controls, the next of kin was
interviewed to collect the data symmetrically,
as described in detail elsewhere.9 Patients who
received estrogen were at the moment of intake
all non-demented. A history of myocardial inf-
arction, hypertension, and hypercholesterolae-
mia was recorded. The presence of at least one
of these three conditions was considered as
vascular pathology. Age at onset was defined as
age when memory failure or changes in behav-
iour were first noted. APOE genotyping was
performed on coded DNA samples without
knowledge of the diagnoses, as described
earlier.10 Data for APOE typing were available
for 82% of the patients and 73% of the
controls.
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STATISTICAL ANALYSIS
The strength of the association between early
onset Alzheimer’s disease and estrogen use was
studied as an odds ratio (OR) in a conditional
logistic regression analysis,11 and presented
with a 95% confidence interval (95% CI). The
dependent variable was case-control status,
and the predictor variables were estrogen use
(present or absent), age (in years) and
education level (primary education only or
more). Stratified analyses according to the
APOE genotype were done with unconditional
logistic regression, a more powerful technique,
as models did not converge with a conditional
approach. Disregarding matching in an uncon-
ditional logistic regression will produce nar-
rower confidence intervals, but the estimated
odds ratios may be biased towards unity.12 An
unconditional logistic regression analysis was
also performed to test for statistical interaction
between estrogen use and the APOE genotype.
We used a product term for estrogen use and
APOE*2 (which included the APOEå2å2 and
APOEå2å3 genotypes), a product term estro-
gen use and APOE*4 (which included
APOEå3å4 and APOEå4å4) in a model that
further included the terms estrogen use,
APOE*2, and APOE*4. There were no women
with the APOEå2å4 genotype. Categorical
variables were studied with the ÷2 test, whereas
for normally distributed, continuous variables,
the two sample t test was used. Based on 109
cases and 119 controls, a significance level of
0.05, and a statistical power of 80%, the small-
est detectable decrease in risk of EOAD was
0.34.
Results
Descriptive statistics of the study population
are presented in table 1. Estrogen use was
reported less often for patients (10%) than for
controls (20%). The age distribution was simi-
lar for patients and controls. Moreover, cases
and controls did not diVer in age at meno-
pause. Table 1 further shows that patients with
early onset Alzheimer’s disease were less
educated than the non-demented controls.
Education level seemed to be related to
estrogen use as well, as higher educated women
more often used estrogen than those with
primary education only (among the controls:
n=16; 28% v n=8; 18%), although not signifi-
cantly (÷2=1.3; df=1; p=0.25).
As shown in table 2, a significant, inverse
association between estrogen use and preva-
lence of early onset Alzheimer’s disease was
found using only matched case-control pairs
(adjusted OR 0.34; 95% CI 0.12–0.94). This
relation held when restrictions were made to
those without vascular pathology (adjusted OR
0.16; 95% CI 0.02–1.31). The inverse associ-
ation between estrogen use and early onset
Alzheimer’s disease seemed to be stronger in
APOE*4 (adjusted OR 0.37; 95% CI 0.08–
1.58) and APOE*2 carriers (OR 0.25; 95% CI
0.02–3.63), than in women with the
APOEå3å3 genotype (adjusted OR 0.60; 95%
CI 0.19–1.88). However, the early onset
Alzheimer’s disease genotype did not signifi-
cantly modify the association between estrogen
use and early onset Alzheimer’s disease, as the
test for statistical interaction between estrogen
use and APOE*4 or APOE*2 yielded p values
of 0.36 and 0.53 respectively.
Discussion
This is the first study on estrogen use and
Alzheimer’s disease with early onset. We found
an inverse association, which held when
restrictions were made for those without
vascular pathology. A limitation of the study is
that the design was observational and data on
estrogen use had to be obtained by informants
due to memory problems in the patients.
Informants were unfortunately not able to
specify the type and duration of estrogen use.
Misclassification of estrogen use might thus
have occurred. However, it should be noted
that in the period of data collection (1980–7),
the eVects of estrogen use were largely
unknown to the general population. It seems
unlikely that relatives of the cases reported
estrogen use less often, compared with inform-
ants for controls. Therefore, any misclassifica-
tion was probably random, and resulted in an
underestimation of the true relation. Although
the cases were not demented at the moment of
estrogen administration, mild memory deficits
may have been present, and we cannot exclude
the possibility that this resulted in a lower
chance of estrogen prescription. It can be
hypothesised that the cases were less likely to
use estrogen because they developed
Alzheimer’s disease before, or soon after
menopause. However, the menopause oc-
curred, on average, 8.3 (SD 8.1) years before
dementia onset and therefore this does not
Table 1 Characteristics of the study population
Cases
(n=109)
Controls
(n=119)
Age at onset (y (SD)) 57.9 (6.4) 58.2 (6.7)*
Age at menopause (y (SD)) 49.6 (4.1) 49.4 (4.4)
Estrogen use:
Yes 11 (10%) 24 (20%)†
No 98 (90%) 95 (80%)
APOE genotype‡:
APOE*2 10 (10%) 23 (25%)
APOE3å3 37 (37%) 44 (48%)
APOE*4 54 (53%) 24 (26%)†
Education:
Primary only 96 (88%) 90 (76%)
Secondary 13 (12%) 29 (24%)†
Vascular pathology:
Present 29 (27%) 47 (39%)†
Absent 80 (73%) 72 (61%)
*Age in controls.
†p< 0.05.
‡APOE genotypes were missing in eight cases and 28 controls;
proportions are based on the available information; APOE*2
denotes APOEå2å2 or APOEå2å3; APOE*4 indicates
APOEå3å4 or APOEå4å4.
Table 2 Odds ratio for early onset Alzheimer’s disease associated with estrogen use
Estrogen use
Crude OR
(95% CI)
Adjusted OR*
(95% CI)
In matched
individuals
(n=208)
In matched
pairs
(n=104)
Yes No
Controls
Yes No
Cases 6 98 Cases Yes 1 5 0.29 (0.11–0.80) 0.34
(0.12–0.94)Controls 18 86 No 17 81
*Adjusted for age and education level using conditional logistic regression.
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seem to be a likely explanation. An advantage
of this study is the population based approach
that minimises selection bias.
In our study population, the administration
of estrogens took place more than 10 years ago
when vascular diseases were among the
contraindications.13 To evaluate confounding
by contraindication, we restricted the analyses
to those without vascular pathology at the
moment of the study. As this is a chronic con-
dition, the absence of vascular pathology at the
moment of the study implies absent vascular
pathology at the moment of administration.We
could still detect an inverse association of
estrogen use with early onset Alzheimer’s
disease in these women, which suggests that
our findings are not due to confounding.
Estrogen may be implicated in Alzheimer’s
disease through several mechanisms. It may be
protective for atherosclerosis,14 and may in-
crease cerebral blood flow.15 As vascular factors
seem to be implicated in Alzheimer’s disease,16
estrogen use may thus have a beneficial eVect
on its development. Secondly, estrogen was
found to have neurotrophic eVects. Estrogen
may promote the activity of growth factors,17
increase neuron viability,17 and maintain neu-
ronal interconnections in brain areas associated
with cognition.18 It further aVects several neu-
rotransmitter systems, in particular the cholin-
ergic system.19 Thirdly, estrogen may favour-
ably modify the processing of amyloid
precursor protein, thereby reducing the accu-
mulation of â-amyloid.17 In addition, the puta-
tive exitotoxic eVects of â-amyloid may be
diminished by estrogen.20 Other possible
mechanisms include the reversal of glucocorti-
coid damage, and anti-inflammatory eVects.17
Epidemiological studies of estrogen use and
late onset Alzheimer’s disease have been
inconsistent.1 Up to now, 11 observational
studies on estrogen use and the risk of demen-
tia have been published, four suggested an
increased risk, and seven a decreased risk of
dementia.1 21 A meta-analysis of 10 of these
investigations reported a 29% decreased risk of
developing dementia associated with estrogen
use.1 There were, however, striking diVerences
in methodology across these studies: two used a
cohort design and eight a case-control ap-
proach. DiVerent diagnostic criteria were used,
and several studies were subject to recall bias. It
should be noted that in the, methodologically
superior, prospective follow up studies a
decreased risk was seen,22 23 which is plausible
given the results from experimental studies
mentioned above. The present study provides
further evidence that estrogen use has a
protective eVect on Alzheimer’s disease, as we
could detect an inverse association with the
early onset type, which is thought to be less
environmentally determined than late onset
Alzheimer’s disease.
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